Healthcare sales up 15% at Novo Nordisk:
This article was originally published in Clinica
Executive Summary
Healthcare sales at Novo Nordisk (Denmark) rose 15% to DKr 2,365 million ($438 million) in the first quarter of 1995 compared with the previous year. This reflects developments in the volume/product mix, says the company. Diabetes care revenues were up DKr 1,610 in the quarter compared with 1994. Stronger sales in Germany, Japan and the UK were counteracted by a decline in US sales, which Novo blames on negative currency exchange movements. Group turnover was up 9% to DKr 3,404 million for the quarter, with net income up 15% to DKr 310 million, compared with the same period last year. The group expects overall revenues to increase some 10% in 1995.